Rocket Pharmaceuticals
RCKT
35 hedge funds and large institutions have $17.9M invested in Rocket Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 21 closing their positions.
450% more call options, than puts
Call options by funds: $33K | Put options by funds: $6K
20% more capital invested
Capital invested by funds: $15M → $17.9M (+$2.97M)
2.03% more ownership
Funds ownership: 7.3% → 9.32% (+2%)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
31% less funds holding
Funds holding: 51 → 35 (-16)
71% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 21
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.06M |
| 2 |
Jennison Associates
New York
|
+$1.78M |
| 3 |
PVI
Pura Vida Investments
New York
|
+$1.31M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.18M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$726K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCP
Rho Capital Partners
New York
|
-$4.99M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$451K |
| 3 |
CCI
Columbus Circle Investors
|
-$417K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$404K |
| 5 |
Goldman Sachs
New York
|
-$330K |
RCKT Hedge Fund Activity: Q3 2017 in Review
35 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q3 2017, worth a combined $17.9M — up 20% from $15M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of RCKT and 6 opened new positions — a net loss of 15 holders — while 12 trimmed existing stakes and 9 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $2.06M. The largest seller was Rho Capital Partners, exiting entirely with an estimated $4.99M sold.
- 35 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q3 2017, down from 51 in Q2 2017.
- Funds reported $17.9M of Rocket Pharmaceuticals stock for Q3 2017, up 20% quarter-over-quarter.
- 6 funds opened new Rocket Pharmaceuticals positions in Q3 2017 and 21 closed out, a net change of -15 holders.
- The largest Rocket Pharmaceuticals buyer in Q3 2017 was Opaleye Management, an estimated $2.06M added.
- The largest Rocket Pharmaceuticals seller in Q3 2017 was Rho Capital Partners, an estimated $4.99M sold.
Based on aggregated 13F filings for Q3 2017.